tradingkey.logo

Emergent BioSolutions Inc <EBS.N> expected to post earnings of 44 cents a share - Earnings Preview

ReutersMay 5, 2025 9:09 PM
  • Emergent BioSolutions Inc EBS.N, EBS is expected to show a fall in quarterly revenue when it reports results on May 7 for the period ending March 31 2025

  • The Gaithersburg Maryland-based company is expected to report a 27.1% decrease in revenue to $219 million from $300.4 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on March 3 2025, for the period ended March 31, was for revenue between $200.00 million and $240.00 million. (Sales/Revenue majority basis is on Total Revenue.)

  • ​LSEG's mean analyst estimate for Emergent BioSolutions Inc is for earnings of 44 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50​, above​ its last closing price of $5.14. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.50

-0.49

0.05

Beat

110.1

Sep. 30 2024

0.13

0.14

1.37

Beat

878.6

Jun. 30 2024

-0.94

-0.94

-2.32

Missed

-145.5​

Mar. 31 2024

-0.87

-0.86

0.59

Beat

168.6

​​Dec. 31 2023

-0.14

-0.19

-0.77

Missed

-305.3

Sep. 30 2023

-0.25

-0.22

-0.48

Missed

-114.9​

Jun. 30 2023

-0.53

-0.49

-1.06

Missed

-117.8

Mar. 31 2023

-1.22

-1.24

-3.17

Missed

-155.6

This summary was machine generated May 5 at 21:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI